ifosfamide has been researched along with Experimental Neoplasms in 32 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Experiments in 214 DS carcinosarcoma bearing Wistar rats have shown that BA 1, at a dosage of only about 12 percent LD50 (150 mg kg) and negligible lethality (1." | 5.25 | [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a ( Ardenne, M; Reitnauer, PG, 1975) |
| "The series of 9 compounds, including 3 racemates and 6 enantiomers of bromine-substituted analogues of ifosfamide (bromo-, chlorobromo- and dibromofosfamides) have been evaluated for antitumor activity against L1210 leukemia, Lewis lung carcinoma and B16 melanoma in mice." | 3.68 | Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds. ( Glazman-Kuśnierczyk, H; Matuszyk, J; Radzikowski, C, 1992) |
| "This study examined the characteristics of urinary bladder lesions (cystitis) induced by ifosfamide (IF), an antitumor agent, and their inhibition by mesna in rats." | 3.68 | [Ifosfamide-induced urinary bladder lesion and its inhibition by mesna]. ( Kasai, H; Matsui, S; Muraoka, Y; Nara, H; Watanabe, H, 1990) |
| "The biologic activity in terms of survival of normal hematopoietic stem, osteosarcoma, and L1210 leukemia cells was determined for the following compounds:cyclophosphamide, its derivatives isophosphamide and trophosphamide, its possible metabolites nor-nitrogen mustard, hydroxylamine mustard, 4-ketocyclophosphamide, and and acrolein, and two substitutes for its primary active metabolite 4-hydroxycyclosphamide anhydro-dimer (4-hydroxy-CP-anhydro-dimer) and 4-hydroperoxycyclophosphamide (4-hydroperoxy-CP)." | 3.65 | Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271). ( Lelieveld, P; van Putten, LM, 1976) |
| "The role of chemotherapy (CHX) in squamous cell carcinoma of the head and neck (SCCHN) has been expanding." | 1.38 | The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent. ( Ekblad, L; Kjellén, E; Mineta, H; Sasaki, Y; Wahlberg, P; Wennerberg, J, 2012) |
| " Thus, neither DSF nor DDTC impaired the antitumour effect of IFX and both diminished its adverse effects." | 1.28 | Drug interaction effects on antitumour drugs (VIII): prevention of ifosfamide-induced urotoxicity by disulfiram and its effect on antitumour activity and acute toxicity of alkylating agents in mice. ( Ishikawa, M; Sasaki, K; Takayanagi, Y, 1991) |
| "Mesna is a pharmacologically unremarkable, physiologically largely inert and almost totally non-toxic thio compound." | 1.26 | Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). ( Brock, N; Pohl, J; Scheef, W; Stekar, J, 1982) |
| "The ANH-nephroblastoma, however, could not be cured even with the highest tolerable doses of ifosfamide." | 1.26 | [Chemotherapeutic activity of ifosfamide in 6 different isologously transplanted experimental tumours of BD-rats (author's transl)]. ( Stekar, J, 1976) |
| " Experiments in 214 DS carcinosarcoma bearing Wistar rats have shown that BA 1, at a dosage of only about 12 percent LD50 (150 mg kg) and negligible lethality (1." | 1.25 | [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a ( Ardenne, M; Reitnauer, PG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (59.38) | 18.7374 |
| 1990's | 8 (25.00) | 18.2507 |
| 2000's | 4 (12.50) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Indrová, M | 3 |
| Bieblová, J | 3 |
| Rossowska, J | 1 |
| Kuropka, P | 1 |
| Pajtasz-Piasecka, E | 3 |
| Bubeník, J | 2 |
| Reinis, M | 2 |
| Sasaki, Y | 1 |
| Kjellén, E | 1 |
| Ekblad, L | 1 |
| Wahlberg, P | 1 |
| Mineta, H | 1 |
| Wennerberg, J | 1 |
| Mikysková, R | 1 |
| Mendoza, L | 1 |
| Símová, J | 1 |
| Jandlová, T | 2 |
| Jinoch, P | 1 |
| Smahel, M | 1 |
| Vonka, V | 2 |
| Hansen, RJ | 1 |
| Ludeman, SM | 1 |
| Paikoff, SJ | 1 |
| Pegg, AE | 1 |
| Dolan, ME | 1 |
| Klein, HO | 1 |
| Wickramanayake, PD | 1 |
| Christian, E | 1 |
| Coerper, C | 1 |
| Graf, L | 1 |
| Miyahara, K | 1 |
| Goldin, A | 1 |
| Barnett, D | 1 |
| Brock, N | 1 |
| Pohl, J | 2 |
| Stekar, J | 2 |
| Scheef, W | 1 |
| Struck, RF | 1 |
| Dykes, DJ | 1 |
| Corbett, TH | 1 |
| Suling, WJ | 1 |
| Trader, MW | 1 |
| Tew, KD | 1 |
| Bertram, B | 1 |
| Hilgard, P | 1 |
| Nowrousian, MR | 1 |
| Stüben, J | 1 |
| Wiessler, M | 1 |
| Wiedemann, GJ | 1 |
| Siemens, HJ | 1 |
| Mentzel, M | 1 |
| Biersack, A | 1 |
| Wössmann, W | 1 |
| Knocks, D | 1 |
| Weiss, C | 1 |
| Wagner, T | 1 |
| Badary, OA | 1 |
| Ardenne, M | 1 |
| Reitnauer, PG | 1 |
| Carter, SK | 1 |
| Slavik, M | 1 |
| Greco, C | 2 |
| Corsi, A | 2 |
| Caputo, M | 1 |
| Cavallari, A | 1 |
| Calabresi, F | 2 |
| Lelieveld, P | 1 |
| van Putten, LM | 1 |
| Glazman-Kuśnierczyk, H | 1 |
| Matuszyk, J | 2 |
| Radzikowski, C | 4 |
| Wallen, CA | 1 |
| Moore, SK | 1 |
| Wheeler, KT | 1 |
| Ishikawa, M | 1 |
| Takayanagi, Y | 1 |
| Sasaki, K | 1 |
| Muraoka, Y | 1 |
| Watanabe, H | 1 |
| Matsui, S | 1 |
| Nara, H | 1 |
| Kasai, H | 1 |
| Berger, DP | 1 |
| Fiebig, HH | 1 |
| Winterhalter, BR | 1 |
| Wallbrecher, E | 1 |
| Henss, H | 1 |
| Kuśnierczyk, H | 3 |
| Brade, W | 1 |
| Seeber, S | 1 |
| Herdrich, K | 2 |
| Paprocka, M | 2 |
| Budzyński, W | 2 |
| Rak, J | 2 |
| Kinas, R | 1 |
| Misiura, K | 1 |
| Stec, W | 1 |
| Brade, WP | 1 |
| Varini, M | 1 |
5 reviews available for ifosfamide and Experimental Neoplasms
| Article | Year |
|---|---|
Ifosfamide in experimental tumor systems.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Ifosfamide; Lethal Dose | 1982 |
Preclinical toxicology of ifosfamide.
Topics: Animals; Cats; Cricetinae; Cyclophosphamide; Dogs; Drug Evaluation, Preclinical; Female; Ifosfamide; | 1982 |
Investigational drugs under study by the United States National Cancer Institute.
Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Ant | 1976 |
Comparative activity of ifosfamide and cyclophosphamide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cystitis; Humans; Ifosfam | 1986 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
1 trial available for ifosfamide and Experimental Neoplasms
| Article | Year |
|---|---|
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
27 other studies available for ifosfamide and Experimental Neoplasms
| Article | Year |
|---|---|
HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proli | 2009 |
The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cisplat | 2012 |
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Cancer Vacci | 2003 |
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Topics: Animals; Cancer Vaccines; Disease Models, Animal; Down-Regulation; Genes, MHC Class I; Genetic Thera | 2006 |
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.
Topics: Acetaldehyde; Acrolein; Alkylating Agents; Animals; CHO Cells; Cricetinae; Cricetulus; Cyclophospham | 2007 |
Therapeutic effects of single-push or fractionated injections of cyclophosphamide or ifosfamide combined with mesna.
Topics: Animals; Cyclophosphamide; Drug Therapy, Combination; Ifosfamide; Male; Mercaptoethanol; Mesna; Mice | 1983 |
[Chemotherapy of a human pseudomyxoma peritonei transplanted in the nude mouse].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenoma; Doxoru | 1984 |
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
Topics: Animals; Cyclophosphamide; Dogs; Drug Interactions; Female; Ifosfamide; Kinetics; Lethal Dose 50; Ma | 1982 |
Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Cyclophosphamide; | 1983 |
Isophosphamide.
Topics: Animals; Carcinogens; Chemical Phenomena; Chemistry; Cyclophosphamide; Female; Humans; Ifosfamide; M | 1981 |
Comparative cytotoxic properties of ifosfamide and cyclophosphamide in rat solid tumor and normal tissues.
Topics: Animals; Bone Marrow; Cyclophosphamide; DNA; DNA, Neoplasm; Ifosfamide; Intestinal Mucosa; Neoplasms | 1982 |
D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport.
Topics: Absorption; Administration, Oral; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Ce | 1995 |
Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide.
Topics: Animals; Body Temperature; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Ifosf | 1993 |
Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice.
Topics: Administration, Oral; Analysis of Variance; Animals; Antineoplastic Agents; Antineoplastic Agents, A | 1999 |
[Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a
Topics: Animals; Antineoplastic Agents; Carcinosarcoma; Cyclophosphamide; Drug Evaluation, Preclinical; Drug | 1975 |
[Chemotherapeutic activity of ifosfamide in 6 different isologously transplanted experimental tumours of BD-rats (author's transl)].
Topics: Animals; Carcinosarcoma; Cyclophosphamide; Female; Ifosfamide; Male; Neoplasms, Experimental; Rats; | 1976 |
Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects.
Topics: Animals; Cyclophosphamide; Ifosfamide; Lethal Dose 50; Lung Neoplasms; Male; Mice; Mice, Inbred C57B | 1979 |
Comparative effects of cyclophosphamide and isophosphamide on Lewis lung carcinoma.
Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Ifosfamide; Lung Neoplasms; Mice; Neopl | 1978 |
Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Topics: Acrolein; Animals; Antineoplastic Agents; Biotransformation; Cells, Cultured; Cyclophosphamide; Dose | 1976 |
Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds.
Topics: Animals; Bromine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ifosfamide; Le | 1992 |
Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Survival; Cyclophosphami | 1992 |
Drug interaction effects on antitumour drugs (VIII): prevention of ifosfamide-induced urotoxicity by disulfiram and its effect on antitumour activity and acute toxicity of alkylating agents in mice.
Topics: Animals; Disulfiram; Ditiocarb; Dose-Response Relationship, Drug; Ifosfamide; Leukopenia; Male; Mice | 1991 |
[Ifosfamide-induced urinary bladder lesion and its inhibition by mesna].
Topics: Animals; Cystitis; Dose-Response Relationship, Drug; Female; Ifosfamide; Injections, Intravenous; Ma | 1990 |
Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.
Topics: Animals; Cyclophosphamide; Drug Evaluation, Preclinical; Drug Resistance; Female; Genital Neoplasms, | 1990 |
Comparative evaluation of acute toxicity and antitumor activity of IF-XXV preparation and holoxan.
Topics: Animals; Female; Ifosfamide; Lethal Dose 50; Leukemia L1210; Lung Neoplasms; Male; Mice; Mice, Inbre | 1989 |
Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
Topics: Animals; Cyclophosphamide; Ifosfamide; Leukemia, Experimental; Mice; Mice, Inbred Strains; Neoplasms | 1986 |
Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Evaluation, Preclinical; Female; Ifosfamide; | 1986 |